Janssen's COVID-19 vaccine submitted to EMA for emergency use

By The Science Advisory Board staff writers

February 17, 2021 -- Johnson & Johnson announced that Janssen has submitted a conditional marketing authorization application to the European Medicines Agency (EMA) for its investigational single-dose Janssen COVID-19 vaccine candidate.

The submission is based on efficacy and safety data from its phase III Ensemble clinical trial. The vaccine candidate was designed using the company's AdVac vaccine platform.

The company announced in December 2020 that it had initiated a rolling submission with the EMA, enabling the agency to review data as it became available. In addition, the company has started rolling submissions in many other countries and with the World Health Organization. An emergency use authorization (EUA) was filed in the U.S. on February 4.

Janssen's investigational single-dose vaccine is estimated to remain stable for two years at -20° C (-4° F), at least three months of which can be stored in most standard refrigerators at temperatures of 2°-8° C (36° F–46° F).

Janssen files EUA for COVID-19 vaccine, FDA sets advisory meeting date
Johnson & Johnson announced that Janssen Biotech has submitted an application to the U.S. Food and Drug Administration (FDA) requesting emergency...
J&J single-shot COVID-19 vaccine meets end points
Johnson & Johnson released efficacy and safety data from its phase III Ensemble clinical trial, which demonstrates that the investigational single-dose...
J&J pauses COVID-19 vaccine trials
Johnson & Johnson on October 12 temporarily paused further dosing in all of its COVID-19 vaccine clinical trials, including the phase III Ensemble...
J&J to supply EU with 200M COVID-19 vaccine doses
Johnson & Johnson has received approval from the European Commission to supply 200 million doses of Janssen Pharmaceutical's COVID-19 vaccine...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter